TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07586306: A Clinical Study Evaluating Subretinal Injection of VGR-R01 in the Contralateral Eye of Participants With Bietti's Crystalline Dystrophy Who Had Received VGR-R01 Administration

Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,637,325

Rescue Site Savings

+$7,004,000

Unlock Full NCT07586306 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07586306 Rescue Dossier →